#United States #New York #Class Action #Zenas BioPharma #ZBIO

Legal Action Against Zenas BioPharma, Inc.

On May 6, 2025, Levi & Korsinsky, LLP announced that it is representing investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) in a class action lawsuit. This legal action is in response to allegations of securities law violations that have adversely impacted shareholders. The suit aims to recover losses incurred by individuals who purchased or otherwise acquired Zenas BioPharma's securities, specifically in relation to the company's initial public offering (IPO) that took place in September 2024.

Class Action Details

The class defined in this lawsuit includes all individuals who made Zenas BioPharma securities transactions related to their IPO. The firm asserts that certain misrepresentations and omissions were made by the company at the time of the offering. The lawsuit claims that defendants falsely stated or concealed the financial realities of Zenas BioPharma's capacity to fund its operations from existing cash and the expected proceeds from the IPO.

Specific Allegations

According to the lawsuit, Zenas BioPharma significantly overstated the duration for which it could sustain operations based on financial forecasts. As a result, public statements made by the company about its financial health were alleged to be materially false and misleading. This puts investors at risk, as it could misrepresent the true business condition and profitability metrics of Zenas BioPharma.

Investors' Rights and Next Steps

Individuals who suffered losses involving Zenas BioPharma, Inc. during the identified timeframe have until June 16, 2025, to request the Court to appoint them as lead plaintiffs in the case. Though becoming a lead plaintiff is an option, potential recovery does not require this status; all affected class members may still be entitled to compensation. Importantly, there are no out-of-pocket costs for those who are part of the class action.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has a long-standing reputation for advocating for shareholder rights. With over 20 years in practice, the firm boasts a record of securing hundreds of millions of dollars in settlements on behalf of injured investors. Their team of over 70 professionals is dedicated to navigating complex securities litigation, and they have been consistently ranked among the top securities litigation firms in the U.S. by ISS Securities Class Action Services. This provides investors with confidence that they are partnering with a firm that knows how to effectively advocate for their interests.

Contact Information

If you are an investor in Zenas BioPharma, and would like to learn more about your rights or the ongoing lawsuit, you can reach out to Joseph E. Levi, Esq. by emailing [email protected] or calling (212) 363-7500. Additionally, further details can be found on their official website, where you can also submit any legal inquiries directly related to the case.

In these volatile market conditions, maintaining vigilance over potential legal violations is crucial for protecting investors’ financial interests. Zenas BioPharma's predicament exemplifies the dynamic landscape of corporate governance and investor relations, reminding shareholders of their rights and the importance of thorough due diligence in investment decisions.